✦ LIBER ✦

Long-term results with cisapride in Parkinson's disease

✍ Scribed by Dr. med. Wolfgang H. Jost; Klaus Schimrigk

Publisher: John Wiley and Sons
Year: 1997
Tongue: English
Weight: 220 KB
Volume: 12
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.870120324

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

In this study, we examined whether there is a longterm effect of cisapride on colonic transit in Parkinson's disease. Twenty‐five patients (11 women, 14 men; average age, 64.4 years; moderate symptoms) were studied and treated initially with cisapride, 5 mg, twice a day, and after the first week with cisapride, 10 mg, twice a day. Colonic transit was measured by radioopaque markers at various stages: after 1 week, 6 months, and 1 year. In untreated patients, transit took 131 h; after 1 week with cisapride, it was accelerated to 81 h. After 6 months, colonic transit time amounted to 99 and to 118 h, respectively, after 1 year. Cisapride seems to be highly effective initially. After 6 months, a significant but reduced effect was seen, and after 1 year, only a small effect could be demonstrated.

📜 SIMILAR VOLUMES

Long-term results of bilateral pallidal

Long-term results of bilateral pallidal stimulation in Parkinson's disease

✍ Jens Volkmann; Niels Allert; Jürgen Voges; Volker Sturm; Alfons Schnitzler; Hans 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views

Effect of cisapride on response fluctuat

Effect of cisapride on response fluctuations in Parkinson's disease

✍ Dr. Ruth Djaldetti; Maya Koren; Ilan Ziv; Anat Achiron; Eldad Melamed 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB 👁 1 views

Long-term antidyskinetic efficacy of ama

Long-term antidyskinetic efficacy of amantadine in Parkinson's disease

✍ Elisabeth Wolf; Klaus Seppi; Regina Katzenschlager; Guenter Hochschorner; Gerhar 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 1 views

## Abstract Several randomized placebo‐controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodop

Long-term results of a multicenter study

Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease

✍ Elena Moro; Andres M. Lozano; Pierre Pollak; Yves Agid; Stig Rehncrona; Jens Vol 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

## Abstract We report the 5 to 6 year follow‐up of a multicenter study of bilateral subthalamic nucleus (STN) and globus pallidus internus (GPi) deep brain stimulation (DBS) in advanced Parkinson's disease (PD) patients. Thirty‐five STN patients and 16 GPi patients were assessed at 5 to 6 years aft

Using global statistical tests in long-t

Using global statistical tests in long-term Parkinson's disease clinical trials

✍ Peng Huang; Christopher G. Goetz; Robert F. Woolson; Barbara Tilley; Douglas Ker 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

## Abstract Parkinson's disease (PD) impairments are multidimensional, making it difficult to choose a single primary outcome when evaluating treatments to stop or lessen the long‐term decline in PD. We review commonly used multivariate statistical methods for assessing a treatment's global impact,

Long-term follow-up of impulse control d

Long-term follow-up of impulse control disorders in Parkinson's disease

✍ Eugenia Mamikonyan; Andrew D. Siderowf; John E. Duda; Marc N. Potenza; Stacy Hor 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB 👁 1 views

## Abstract Recent studies have linked dopamine agonist (DA) usage with the development of impulse control disorders (ICDs) in Parkinson's disease (PD). Little is known about optimal management strategies or the long‐term outcomes of affected patients. To report on the clinical interventions and lo